Eloine N. Bestion

Marseille, 13006, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Tropheryma whipplei escapes LAPosome and modulates macrophage response in a xenophagy-dependent manner.

Tropheryma whipplei escapes LAPosome and modulates macrophage response in a xenophagy-dependent manner.

Journal: Autophagy reports
Published: May 21, 2025

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.

Journal: British journal of pharmacology
Published: October 03, 2024

Autophagy in cancer resistance: New combinatorial strategy for cancer therapy.

Autophagy in cancer resistance: New combinatorial strategy for cancer therapy.

Journal: Leukemia
Published: May 28, 2024

Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma.

Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma.

Journal: Targeted oncology
Published: November 20, 2023

Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors.

Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors.

Journal: Cells
Published: May 19, 2023

Cell and Animal Models for SARS-CoV-2 Research.

Cell and Animal Models for SARS-CoV-2 Research.

Journal: Viruses
Published: May 24, 2022

GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.

GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.

Journal: Viruses
Published: November 22, 2021

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.

Journal: Autophagy
Published: November 06, 2021

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

Journal: Liver cancer
Published: September 27, 2021

GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer.

GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer.

Journal: Journal of Cancer
Published: January 22, 2021

GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.

GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.

Journal: bioRxiv : the preprint server for biology
Published: October 14, 2020

Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.

Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.

Journal: The Journal of infectious diseases
Published: October 13, 2020
Showing 1-12 of 13

Last Updated: 09/26/2026